MiNK Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:INKT

Comments

MiNK Therapeutics Inc Earnings Estimates

INKTNASDAQ

Trade with Public

$9.41

-0.33-3.39%

At close: Mar 20, 5:00 PM EST

$9.30

-0.11-1.17%

After Hours: 6:25 PM EST

Earnings: Q4 2025 Earnings in 11 days from now on Tue Mar 31st, before the market open

Overview NewsEarningsAnalyst Ratings Insider Trades Short Interest Stock Report

MiNK Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:INKT

MiNK Therapeutics (INKT) is scheduled to report Q4 earnings on March 31, 2026. Analysts estimate EPS of $-0.68 and quarterly revenue of N/A.

In the most recent quarter (Q3), MiNK Therapeutics reported EPS of $-0.65, beating estimates of $-0.86 by 0.24%. Revenue came in at $0.00, meeting the estimate of $0.00 by 0.00%.

Over the last 4 quarters, MiNK Therapeutics has averaged an EPS surprise of 0.39% and a revenue surprise of 0.00%.

Earnings Date

Mar 31

EPS Estimate

$-0.680

Quarterly Revenue Estimate

–

Annual Revenue
(as of Sep 30)

–

MiNK Therapeutics Earnings History

Analyze the earnings history of MiNK Therapeutics using advanced sorting and filters.

Loading calendar...

MiNK Therapeutics (INKT) Earnings Per Share

The chart below shows MiNK Therapeutics's reported EPS compared to analyst estimates over recent quarters.

MiNK Therapeutics (INKT) Revenue

The chart below shows MiNK Therapeutics's reported revenue compared to analyst estimates over recent quarters.

FAQ

When is MiNK Therapeutics (NASDAQ:INKT) reporting earnings?

MiNK Therapeutics (INKT) is scheduled to report earnings on May 14, 2026. The last reported earnings were for reported on November 14, 2025 for Q3.

What were the latest earnings per share (EPS) for MiNK Therapeutics (NASDAQ:INKT)?

The Actual EPS was $-0.65, which beat the estimate of $-0.86.

What were MiNK Therapeutics’s (NASDAQ:INKT) revenues?

The Actual Revenue was $0.00, which hit the estimate of $0.00.

People Also Watch

Kezar Life Sciences Inc

NASDAQ:KZR

$6.43

Estrella Immunopharma Inc

NASDAQ:ESLA

$1.16

11.54%

Aligos Therapeutics Inc

NASDAQ:ALGS

$6.81

Atossa Therapeutics Inc

NASDAQ:ATOS

$5.33

Sensei Biotherapeutics Inc

MiNK Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:INKT

MiNK Therapeutics (INKT) is scheduled to report Q4 earnings on March 31, 2026. Analysts estimate EPS of $-0.68 and quarterly revenue of N/A.

In the most recent quarter (Q3), MiNK Therapeutics reported EPS of $-0.65, beating estimates of $-0.86 by 0.24%. Revenue came in at $0.00, meeting the estimate of $0.00 by 0.00%.

Over the last 4 quarters, MiNK Therapeutics has averaged an EPS surprise of 0.39% and a revenue surprise of 0.00%.

Earnings Date

Mar 31

EPS Estimate

$-0.680

Quarterly Revenue Estimate

–

Annual Revenue
(as of Sep 30)

–